# 5E Advanced Materials, Inc.: financial statements, quarterly

FEAM · Nasdaq · CIK 1888654 · [Materials](/sectors/materials.md) · fiscal year ends Jun 30

Pages: [Overview](/companies/feam.md) · [Financials](/companies/feam/financials.md) · [Filings](/companies/feam/filings.md) · [Insiders](/companies/feam/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/feam/financials.md?period=annual).

## Income statement

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | [0.0](/filings/0000950170-24-126394.md) | [0.0](/filings/0000950170-25-019943.md) | [0.0](/filings/0000950170-25-072736.md) | [0.0 d](/filings/0001193125-25-223170.md) | [0.0](/filings/0000950170-24-126394.md) | [0.0](/filings/0000950170-25-019943.md) | [0.0](/filings/0000950170-25-072736.md) | [0.0 d](/filings/0001193125-25-223170.md) | not reported | not reported | not reported | not reported |
| Operating income | $m | [(7.7)](/filings/0000950170-24-126394.md) | [(8.9)](/filings/0000950170-25-019943.md) | [(4.2)](/filings/0000950170-25-072736.md) | [(15.1) d](/filings/0001193125-25-223170.md) | [(12.9)](/filings/0001193125-25-280134.md) | [(11.0)](/filings/0001193125-26-054543.md) | [(10.2)](/filings/0001193125-26-219331.md) | [(9.6) d](/filings/0001193125-26-394541.md) | [(10.7)](/filings/0001193125-25-280134.md) | [(10.9)](/filings/0001193125-26-054543.md) | [(12.3)](/filings/0001193125-26-219331.md) | [(9.4) d](/filings/0001193125-26-394541.md) |
| Interest expense | $m | [1.8](/filings/0000950170-24-126394.md) | [1.7](/filings/0000950170-25-019943.md) | [0.8](/filings/0000950170-25-072736.md) | [1.9 d](/filings/0001193125-25-223170.md) | [2.2](/filings/0001193125-25-280134.md) | [2.4](/filings/0001193125-26-054543.md) | [1.9](/filings/0001193125-26-219331.md) | [0.0 d](/filings/0001193125-26-394541.md) | [0.0](/filings/0001193125-25-280134.md) | [0.0](/filings/0001193125-26-054543.md) | [0.0](/filings/0001193125-26-219331.md) | [0.0 d](/filings/0001193125-26-394541.md) |
| Income tax | $m | [0.0](/filings/0000950170-24-126394.md) | [0.0](/filings/0000950170-25-019943.md) | [0.0](/filings/0000950170-25-072736.md) | [0.0 d](/filings/0001193125-25-223170.md) | [0.0](/filings/0001193125-25-280134.md) | [0.0](/filings/0001193125-26-054543.md) | [0.0](/filings/0001193125-26-219331.md) | [0.2 d](/filings/0001193125-26-394541.md) | [0.0](/filings/0001193125-25-280134.md) | [0.0](/filings/0001193125-26-054543.md) | [0.0](/filings/0001193125-26-219331.md) | [0.0 d](/filings/0001193125-26-394541.md) |
| Net income | $m | [(9.4)](/filings/0000950170-25-072736.md) | [(10.6)](/filings/0000950170-25-072736.md) | [(25.9)](/filings/0000950170-25-072736.md) | [(16.1) d](/filings/0001193125-25-223170.md) | [(12.9)](/filings/0001193125-26-219331.md) | [(14.3)](/filings/0001193125-26-219331.md) | [5.3](/filings/0001193125-26-219331.md) | [(9.7) d](/filings/0001193125-26-394541.md) | [(10.7)](/filings/0001193125-26-219331.md) | [(10.9)](/filings/0001193125-26-219331.md) | [(12.1)](/filings/0001193125-26-219331.md) | [(9.2) d](/filings/0001193125-26-394541.md) |
| Diluted EPS | $ per share | [(0.21)](/filings/0000950170-24-126394.md) | [(0.24)](/filings/0000950170-25-019943.md) | [(10.18)](/filings/0000950170-25-072736.md) | not reported | [(4.52)](/filings/0001193125-25-280134.md) | [(4.76)](/filings/0001193125-26-054543.md) | [(0.97)](/filings/0001193125-26-219331.md) | not reported | [(0.51)](/filings/0001193125-25-280134.md) | [(0.48)](/filings/0001193125-26-054543.md) | [(0.35)](/filings/0001193125-26-219331.md) | not reported |
| Basic EPS | $ per share | [(0.21)](/filings/0000950170-24-126394.md) | [(0.24)](/filings/0000950170-25-019943.md) | [(10.18)](/filings/0000950170-25-072736.md) | not reported | [(4.52)](/filings/0001193125-25-280134.md) | [(4.76)](/filings/0001193125-26-054543.md) | [0.73](/filings/0001193125-26-219331.md) | not reported | [(0.51)](/filings/0001193125-25-280134.md) | [(0.48)](/filings/0001193125-26-054543.md) | [(0.35)](/filings/0001193125-26-219331.md) | not reported |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [11.8](/filings/0000950170-23-062193.md) | [2.0](/filings/0000950170-24-015187.md) | [8.0](/filings/0000950170-24-049412.md) | [4.9](/filings/0001193125-25-223170.md) | [6.9](/filings/0000950170-24-126394.md) | [0.8](/filings/0000950170-25-019943.md) | [4.0](/filings/0000950170-25-072736.md) | [3.8](/filings/0001193125-26-394541.md) | [5.5](/filings/0001193125-25-280134.md) | [0.6](/filings/0001193125-26-054543.md) | [25.4](/filings/0001193125-26-219331.md) | [19.5](/filings/0001193125-26-394541.md) |
| Current assets | $m | [13.1](/filings/0000950170-23-062193.md) | [3.5](/filings/0000950170-24-015187.md) | [10.0](/filings/0000950170-24-049412.md) | [6.8](/filings/0001193125-25-223170.md) | [8.1](/filings/0000950170-24-126394.md) | [1.5](/filings/0000950170-25-019943.md) | [4.6](/filings/0000950170-25-072736.md) | [4.6](/filings/0001193125-26-394541.md) | [5.9](/filings/0001193125-25-280134.md) | [1.1](/filings/0001193125-26-054543.md) | [25.8](/filings/0001193125-26-219331.md) | [20.1](/filings/0001193125-26-394541.md) |
| Total assets | $m | [95.7](/filings/0000950170-23-062193.md) | [87.1](/filings/0000950170-24-015187.md) | [97.0](/filings/0000950170-24-049412.md) | [89.5](/filings/0001193125-25-223170.md) | [85.8](/filings/0000950170-24-126394.md) | [74.8](/filings/0000950170-25-019943.md) | [73.4](/filings/0000950170-25-072736.md) | [70.7](/filings/0001193125-26-394541.md) | [68.7](/filings/0001193125-25-280134.md) | [58.6](/filings/0001193125-26-054543.md) | [78.1](/filings/0001193125-26-219331.md) | [68.0](/filings/0001193125-26-394541.md) |
| Current liabilities | $m | [9.2](/filings/0000950170-23-062193.md) | [9.0](/filings/0000950170-24-015187.md) | [7.3](/filings/0000950170-24-049412.md) | [9.7](/filings/0001193125-25-223170.md) | [7.5](/filings/0000950170-24-126394.md) | [9.4](/filings/0000950170-25-019943.md) | [6.1](/filings/0000950170-25-072736.md) | [6.4](/filings/0001193125-26-394541.md) | [7.4](/filings/0001193125-25-280134.md) | [5.9](/filings/0001193125-26-054543.md) | [4.0](/filings/0001193125-26-219331.md) | [2.8](/filings/0001193125-26-394541.md) |
| Total liabilities | $m | [51.0](/filings/0000950170-23-062193.md) | [52.1](/filings/0000950170-24-015187.md) | [71.5](/filings/0000950170-24-049412.md) | [78.8](/filings/0001193125-25-223170.md) | [83.7](/filings/0000950170-24-126394.md) | [83.2](/filings/0000950170-25-019943.md) | [7.1](/filings/0000950170-25-072736.md) | [7.5](/filings/0001193125-26-394541.md) | [8.5](/filings/0001193125-25-280134.md) | [7.0](/filings/0001193125-26-054543.md) | [5.1](/filings/0001193125-26-219331.md) | [3.9](/filings/0001193125-26-394541.md) |
| Long-term debt | $m | [63.7](/filings/0000950170-23-062193.md) | [63.6](/filings/0000950170-24-015187.md) | [65.7](/filings/0000950170-24-049412.md) | [71.7](/filings/0001193125-25-223170.md) | [81.1](/filings/0000950170-24-126394.md) | [81.1](/filings/0000950170-25-019943.md) | [0.0](/filings/0000950170-25-072736.md) | [0.0](/filings/0001193125-26-394541.md) | [0.0](/filings/0001193125-25-280134.md) | [0.0](/filings/0001193125-26-054543.md) | [0.0](/filings/0001193125-26-219331.md) | [0.0](/filings/0001193125-26-394541.md) |
| Current portion of debt | $m | [0.0](/filings/0000950170-23-062193.md) | [0.0](/filings/0000950170-24-015187.md) | [0.0](/filings/0000950170-24-049412.md) | [0.0](/filings/0001193125-25-223170.md) | [0.0](/filings/0000950170-24-126394.md) | [0.0](/filings/0000950170-25-019943.md) | [0.0](/filings/0000950170-25-072736.md) | [0.0](/filings/0001193125-26-394541.md) | [0.0](/filings/0001193125-25-280134.md) | [0.0](/filings/0001193125-26-054543.md) | [0.0](/filings/0001193125-26-219331.md) | [0.0](/filings/0001193125-26-394541.md) |
| Shareholders' equity | $m | [44.8](/filings/0000950170-25-072736.md) | [35.0](/filings/0000950170-25-072736.md) | [25.5](/filings/0000950170-25-072736.md) | [10.7](/filings/0001193125-26-394541.md) | [2.1](/filings/0001193125-26-219331.md) | [(8.4)](/filings/0001193125-26-219331.md) | [66.3](/filings/0001193125-26-219331.md) | [63.2](/filings/0001193125-26-394541.md) | [60.2](/filings/0001193125-26-219331.md) | [51.6](/filings/0001193125-26-219331.md) | [73.0](/filings/0001193125-26-219331.md) | [64.1](/filings/0001193125-26-394541.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(6,886)](/filings/0000950170-24-126394.md) | [(7,886) d](/filings/0000950170-25-019943.md) | [(4,865) d](/filings/0000950170-25-072736.md) | [(7,235) d](/filings/0001193125-25-223170.md) | [(6,375)](/filings/0001193125-25-280134.md) | [(5,302) d](/filings/0001193125-26-054543.md) | [(5,730) d](/filings/0001193125-26-219331.md) | [(6,233) d](/filings/0001193125-26-394541.md) | [(4,298)](/filings/0001193125-25-280134.md) | [(5,225) d](/filings/0001193125-26-054543.md) | [(4,269) d](/filings/0001193125-26-219331.md) | [(5,248) d](/filings/0001193125-26-394541.md) |
| Capital expenditure | $k | [51.0](/filings/0000950170-24-126394.md) | [0.0 d](/filings/0000950170-25-019943.md) | [37.0 d](/filings/0000950170-25-072736.md) | [0.0 d](/filings/0001193125-25-223170.md) | [11.0](/filings/0001193125-25-280134.md) | [0.0 d](/filings/0001193125-26-054543.md) | [93.0 d](/filings/0001193125-26-219331.md) | [20.0 d](/filings/0001193125-26-394541.md) | [919](/filings/0001193125-25-280134.md) | [1,302 d](/filings/0001193125-26-054543.md) | [4,337 d](/filings/0001193125-26-219331.md) | [0.0 d](/filings/0001193125-26-394541.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q1 FY2023 (2022-09-30) | Q2 FY2023 (2022-12-31) | Q3 FY2023 (2023-03-31) | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [48.5](/filings/0000950170-23-062193.md) | [43.8](/filings/0000950170-24-015187.md) | [44.1](/filings/0000950170-24-049412.md) | [44.2](/filings/0000950170-24-126394.md) | [44.2](/filings/0000950170-25-019943.md) | [2.5](/filings/0000950170-25-072736.md) | [2.8](/filings/0001193125-25-280134.md) | [3.0](/filings/0001193125-26-054543.md) | [10.5](/filings/0001193125-26-219331.md) | [21.0](/filings/0001193125-25-280134.md) | [22.7](/filings/0001193125-26-054543.md) | [34.9](/filings/0001193125-26-219331.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 41,647,371 at 2026-09-16, from the cover of the [10-K filed 2026-09-17](/filings/0001193125-26-394541.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.